We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

GE Launches Drawbridge Health to Transform Blood Collection

By LabMedica International staff writers
Posted on 05 Dec 2017
GE Healthcare (Chicago, IL, USA) has introduced Drawbridge Health, a privately held healthcare technology company, which is developing a people-friendly system to integrate draw, collection and stabilize blood samples into a single device. The technology which integrates engineering and proprietary chemistries is also being developed to support room temperature shipping and streamlined downstream processing, thus ensuring reliable, accurate results.

The Drawbridge solution will allow healthcare providers and diagnostic testing companies to deliver a superior patient experience by eliminating the need for phlebotomy and travel to blood draw centers. Drawbridge expects its blood draw solution to alter the market for patients and healthcare providers by broadening the availability and access for molecular tests for a variety of diseases, as well as providing a convenient way to monitor overall health, therapy response and disease progression.

“At GE we share technology, markets, structure and knowledge across our varied businesses, which uniquely positions us to tackle many issues, including this one,” said Risa Stack, Managing Director of New Business Creation, GE Ventures. “With Drawbridge Health, we are combining technology from GE Global Research, expertise from GE Healthcare and business models from GE Ventures to offer a simple, safe and more efficient solution that can help save time, money and lives.”

“At Drawbridge Health, we have a tremendous opportunity to uniquely enable not only effortless access to diagnostic testing, but to also transform how diagnostics companies and healthcare providers interact with their patient-consumers,” said Lee McCracken, CEO, Drawbridge Health.

“The current sample testing process is inconvenient and challenging for patients and medical providers, alike. It requires clinical processing equipment, often a technician specifically trained to draw blood, plus a trip to the doctor’s office or hospital. By combining world class GE technology and a talented founding team to address an important market need, Drawbridge Health is well positioned to transform diagnostic testing for healthcare stakeholders, testing laboratories, patients and consumers.”


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Latest Industry News

Siemens to Close Fast Track Diagnostics Business

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems